Chrysalis, a provider of GMP cleanroom hosting and support services for advanced therapy and biopharma companies, has appointed Adam Bartley as chief operating officer.

Bartley will oversee day-to-day operations across Chrysalis’ cleanroom infrastructure, environmental monitoring, and support service teams, strengthening the company’s operational capabilities as it grows its portfolio of advanced therapy clients.

Bringing more than 24 years of leadership experience in biopharmaceutical operations, Bartley has held senior roles at Wyeth, Shire, and Sanofi. He also has direct experience with Chrysalis as a former client, having partnered with the company to launch and operate cleanroom-based manufacturing at Editas Medicine.

“As a client, I saw the value Chrysalis brings to growing biotechs – cutting out complexity and significant capital expenditure so teams can focus on science and execution,” Bartley said. “I’m excited to now be on the inside, helping scale that model and push operational boundaries to support even more clients.”

Sarah Stevens, CEO of Chrysalis, added: “Adam’s deep operational and leadership experience is only strengthened by his unique understanding of our Chrysalis operating model. He’s lived our customer experience first-hand, and brings a pragmatic, continuous improvement mindset that complements our ability to enable speed, quality, and flexibility for our customers.”

Bartley’s appointment comes as Chrysalis continues to invest in people and operational excellence to support clients from development through GMP clinical and commercial production.